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1. Introduction 
Neovascular glaucoma (NVG) is an intractable sight-threatening disease which is extremely 
difficult to manage and can lead to permanent visual loss. It occurs as a result of iris neo-
vascularization also known as rubeosis iridis. Once the condition develops, early diagnosis 
and management is essential to minimize visual loss, thus better understanding of the 
causes and pathogenesis is essential. The objective of this chapter is to discuss the causes, 
pathogenesis and management options of NVG.  
2. Pathogenesis and pathology of NVG 
NVG is defined as rubeosis iridis or iris neovascularization (NVI) with secondary angle-
closure glaucoma. It is a serious sequela of ischaemic eye diseases.  
2.1 Grading of iris neovascularization 
A grading system for NVI was proposed by Teich and Walsh (Teich, 1981), and is shown in 
Table 1.  
 
Grade  
0 No iris neovascularization 
1 Less than 2 quadrants of NV at iris pupillary zone  
2 More than 2 quadrants of NV at iris pupillary zone 
3 Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or 
ectropion uveae 
4 More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae 
Table 1. Grading of NVI (Teich, 1981) 
2.2 Pathogenesis of NVG 
Retinal hypoxia is central in the pathogenesis of NVG. Ischaemia triggers release of factors 
that both inhibit and promote neovascularization (Brown, 1984), but greater concentrations 
of the former result in rubeosis. Such vasoproliferative factors include vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF) and others. Intraocular concentrations 
of VEGF were found to be increased in patients with active proliferative diabetic 
retinopathy (PDR), central retinal vein occlusion (CRVO) and retinopathy of prematurity 
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(ROP) (Aeillo, 1994; Malecaze, 1994; Adamis, 1994). VEGF was subsequently implicated in 
the pathogenesis of choroidal neovascularization in age-related macular degeneration. A 
close temporal correlation between aqueous VEGF and degree of iris neovascularization has 
been recorded (Hayreh, 2007). Infarcted retina, such as in central retinal artery occlusion 
(CRAO) does not cause production of VEGF or other growth factors, and thus is not 
associated with a risk of neovascularization and NVG.  
VEGF is an endothelial cell specific mitogen, and is synthesized by several types of retinal 
cells, the primary source being Muller cells. Once VEGF is released, it causes rubeosis if it 
reaches the iris and angle; something which happens when the lens is removed, especially if 
the posterior capsule is breached (Rice, 1983). VEGF is also secreted by hypoxic 
retinoblastoma, causing rubeosis irides in eyes with the tumour (Pe’er, 1997).  
The disease develops in 3 stages: 
Neovascularization of the iris (NVI) : tiny tufts of vessels grow on the anterior surface of the 
iris, starting in most cases, but not invariably, at the pupillary border in many cases as that is 
the site of maximal turnover of aqueous containing growth factors. These vessels form 
before pressure rises.  
Secondary open angle glaucoma (SOAG): The NVI extend to involve the angle, and are 
accompanied by fibrosis, invisible on gonioscopy, blocking the trabecular meshwork and 
causing ocular hypertension, and SOAG. Neovascular tissue found in the trabecular spaces 
might be one of the factors responsible for intraocular pressure elevation in eyes with 
neovascular glaucoma (Kubota, 1996). 
Secondary angle closure glaucoma (SACG): Myofibroblasts within the fibrovascular tissue 
proliferate and contract, forming peripheral anterior synechiae (PAS), and secondary angle 
closure, with resulting intra-ocular pressure rise.  
Animal experimental models have demonstrated the presence of inflammatory cells in the 
iris stroma, epithelium and on the surface of the fibroneovascular membrane during NVI 
formation (Hjelmeland, 1992). The active role of inflammation in the condition is further 
confirmed by the presence of NVG in non-ischaemic inflammatory eye diseases including 
Vogt-Koyanagi-Harada disease, endophthalmitis, chronic uveitis and Fuchs’ heterochromic 
iridocyclitis (Feys, 1994; Norose 1994; Lappin 1997).  
Interleukin-6 (IL-6) has also been implicated in the pathogenesis of NVG. Increased aqueous 
concentrations of IL-6 have been correlated temporally and spatially with the grade of iris 
NV in patients with NVG secondary to CRVO (Chen, 1999). IL-6 expression was shown to 
increase in rat retina after transient ischaemia (Hangai, 1996). Studies are required to 
investigate whether IL-6 levels can be used as predictors of NVG.  
Transforming growth factor (TGF)-beta was also noted to be increased in the aqueous of 
eyes with NVG and might be implicated in formation and contraction of iris neovascular 
membranes (Yu, 2007).  
3. Causes of NVG 
The main cause of neovascular glaucoma is severe retinal ischaemia, as a result of which 
vasoproliferative growth factors are produced to attempt revascularization of the hypoxic 
areas. This process can result in neovascularization of the iris (NVI) and of the angle (NVA) 
of the anterior chamber, thus causing secondary glaucoma. Only 3% of cases of NVG are 
caused by inflammation without retinal ischaemia (Brown, 1984). 
By far the commonest causes of NVG are proliferative diabetic retinopathy, ischaemic 
central retinal vein occlusion (CRVO) and ocular ischaemic syndrome. However, there are 
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reports of other conditions which have been associated with NVG and they are shown in 
Table 2.  
 
 
Diabetic Retinopathy 
Retinal Vascular Occlusive Diseases 
 Central Retinal Vein Occlusion 
 Ischaemic Hemiretinal Vein Occlusion 
Ocular Ischaemic Syndrome 
 Carotid Artery Occlusive Disease 
 Takayasu’s Syndrome 
 Carotid-Cavernous Fistula 
 Giant Cell Arteritis 
 Wyburn-Mason syndrome 
 Strabismus Surgery 
Ocular Radiation 
Tumours 
 Uveal Melanomas 
 Metastatic Choroidal Tumours 
 Medulloepithelioma 
 Retinoblastoma 
 Pigmented Ciliary Adenocarcinoma 
 Metastatic Malignant Lymphoma 
Other 
 Uveitis 
 Retinal Vasculitis 
 Coat’s Disease 
 Eales’ Disease 
 Sarcoidosis 
 X-linked Retinoschisis 
 Chronic Retinal Detachment 
 Retinopathy of Prematurity 
 Systemic Cryoglobulinaemia 
 
Table 2. Causes of Neovascular Glaucoma 
3.1 Diabetic retinopathy 
It is well known that neovascular glaucoma can arise in diabetic retinopathy. In eyes with 
proliferative diabetic retinopathy, the incidence of NVI is 65% (Ohrt, 1961). The causative 
mechanism that is widely accepted is the presence of severe diffuse retinal ischaemia, which 
in turn promotes production of neovascular growth factors.  
In one study, retinal non-perfusion was classified according to the area of retina involved 
in the midperiphery (Hamanaka, 2001). Area of retinal non-perfusion greater than 50% 
was a statistically significant risk factor for NVA. Eyes with new vessels at the optic disc 
(NVD) also have increased risk of NVA. As the NVA results in anterior synechiae and 
secondary closure of the angle, advancement of NVA therefore increases the risk of high 
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intra-ocular pressure (IOP). This, however, also depends on the individual anatomy of the 
trabecular meshwork in the individual’s angle, as the elevation of IOP depends on the 
amount of space left in the trabecular meshwork following NVA and anterior synechial 
formation.  
Diabetic iridopathy has been graded by the extent of rubeosis (Laatikainen, 1979): 
Grade I. Peripupillary vessel dilatations (dilated leaking vessels around the pupil) 
Grade II. Early neovascularization in the angle (small, irregular arborizing superficial 
newly formed vessels in the angle, associated with an open angle). 
Grade III. Prominent rubeosis with or without NVG (vessels grown out of the angle, 
affecting more of the iris surface 
Grade IV. Florid rubeosis (associated with angle closure) 
3.2 Retinal vascular occlusive diseases 
NVG is a complication of ischaemic CRVO (Hayreh, 1982). Distinction between ischaemic 
and non-ischaemic RVO is based on a number of criteria (Hayreh, 1990; The Central 
Retinal Vein Occlusion Group, 1995). Visual acuity tends to be worse than 6/120 in 
ischaemic CRVO, with a relative afferent pupillary defect (RAPD) present and a b-wave 
amplitude of less than 60% on electroretinography (ERG). The information provided by 
FFA is limited. Studies have shown that eyes with 75 disc diameters or more of ischaemia 
(capillary dropout) are most at risk of resulting in neovascularization, the maximum risk 
being in the first 7-8 months from diagnosis. Like CRVO, NVG is also a complication of 
ischaemic hemicentral retinal vein occlusion (HCRVO), occurring in 3% of cases (Hayreh, 
1982).  
3.3 Ocular Ischaemic syndrome 
Ocular ischaemic syndrome (OIS) is caused by reduction of blood flow to the eyeball and 
manifests itself as anterior and/or posterior segment ischaemia. Most cases are caused by 
carotid artery occlusive disease (CAOD), which accounts for 13% of all cases of NVG. It is 
diagnosed with carotid Doppler ultrasound and carotid angiography. Apart from OIS, 
CAOD can also cause brain ischaemia (transient ischaemic attacks or cerebral vascular 
accidents) and embolic retinal artery occlusions. However, OIS can be caused by other 
diseases, including Takayasu’s syndrome, Carotid-cavernous fistula, giant cell arteritis, 
Wyburn-Mason syndrome and iatrogenic causes such as strabismus surgery (Saunders, 
1994). An important differentiating feature among OIS, CRVO and diabetic retinopathy is 
low retinal arterial pressure (Mendrinos, 2010) and this can be tested in clinical practice by 
light digital pressure on the globe, which induces retinal artery pulsations in eyes with OIS. 
It is also important to note that pain in OIS is not always attributable to NVG, as ischaemic 
pain occurs in up to 40% of eyes with OIS.  
3.4 Ocular radiation 
It is well recognized that radiation for ocular and orbital lesions can lead to NVG, and this is 
due to radiation retinopathy. This can occur as a result of exposure to any source of 
radiation, including external beam and plaque radiotherapy. For instance, radiation 
retinopathy has been reported to occur in 10-63% of eyes treated for choroidal melanoma 
with plaque radiotherapy (Wen, 2009; Foss, 1997). Apart from choroidal melanomas, 
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radiation has been used for a number of lesions, including iris melanomas, choroidal 
metastatic tumours, optic nerve glioma, retinoblastoma, orbital lymphoma and nasal 
malignancies. The ensuing retinal ischaemia can lead to NVG.  
3.5 Tumours 
NVG has been associated with choroidal melanomas, the mechanism being attributed to 
release of angiogenic factors, serous retinal detachment with secondary retinal ischaemia, 
retinal vascular occlusion by direct invasion by the tumour, inflammation and radiation 
retinopathy (Lee, 2001). Reports of other tumours causing NVG have been documented, 
including ring melanoma of anterior uvea, medulloepithelioma, choroidal haemangioma, 
metastatic cutaneous melanoma, retinoblastoma, pigmented ciliary adenocarcinoma and 
metastatic malignant lymphoma (Hayreh, 2007; Schalenbourg, 2008).  
3.6 Other Causes 
NVG has also been documented in cases of retinal vasculitis (Salmon, 2000), Coat’s disease 
(Shields, 2007; Shields, 2001), Eales disease (Atmaca, 2002), sarcoidosis (Gaskin, 2005), X-
linked retinoschisis (Rosenfeld, 1998), uveitis, chronic retinal detachment, retinopathy of 
prematurity and systemic conditions such as cryoglobulinaemia (Telander, 2006) and 
Neurofibromatosis I (Elgi, 2010). NVG can occur in anterior, posterior or panuveitis and can 
be due to the inflammation itself, anterior segment ischaemia, or the underlying causative 
condition such as Crohn’s disease. Uveitis in the presence of chronic iridocyclitis, Fuch’s 
uveitis syndrome, scleritis and carotid occlusive disease (OIS) has been especially implicated 
in NVG (Perry, 1975; Coppeto, 1985). 
4. Diagnosis of NVG 
A high index of suspicion in context of the above diseases is required to diagnose early 
NVG, where intra-ocular pressure is not elevated and only subtle signs are present. In most 
cases, neovascularization of the iris starts as fine vessels at the pupillary margin and can be 
easy to miss. Examination of the iris and gonioscopy with an undilated pupil is essential. 
Careful gonioscopy is required to detect NVA and anterior synechiae. The CRVO study 
found that 6% of eyes with ischaemic CRVO had NVA without iris new vessels (CRVO 
Study Group, 1993). In fact, undilated gonioscopy should be performed on all patients at 
risk of developing NVG. Fluorescein iris angiography can be useful in differentiating iris 
neovascularization from normal iris vessels as the latter do not leak fluorescein. Anterior 
chamber cells and flare can accompany rubeosis due to leakage of the abnormal vessels, and 
can be misdiagnosed as anterior uveitis.  
Studies on pupil reactions in patients with CRVO revealed that a relative afferent pupillary 
defect of 0.6 log units was 83% sensitive and 70% specific in predicting development of 
rubeosis in patients with CRVO (Bloom, 1993). However, further studies on pupil 
examination in disease processes are needed.  
Fundus fluorescein angiography (FFA) is important in illustrating the extent and area of 
retinal ischaemia. Electroretinogram (ERG) can help in diagnosing retinal ischaemia. More 
recently, anterior chamber optical coherence tomography (AS-OCT) and ultrasound 
biomicroscopy (UBM) illustrates anterior segment structures in great detail and are being 
used more frequently in diagnosing and staging of the disease.  
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Ultimately, a high index of suspicion and undilated gonioscopy is central in the diagnosis of 
neovascular glaucoma.  
5. Management 
Management of neovascular glaucoma can be divided into treatment of the underlying 
disease process responsible for rubeosis, and management of the elevated intra-ocular 
pressure which develops.  
5.1 Treatment of underlying disease 
Evidence for treatment of diabetic retinopathy is based on various studies. More specifically 
to NVG, the Diabetic Retinopathy Study (DRS) determined that laser photocoagulation 
reduces the risk of severe visual loss by 50% compared with no treatment (The Diabetic 
Retinopathy Study Research Group, 1981), and is the treatment of choice for prevention of 
NVG in diabetic eyes. Ohnishi et al documented regression of rubeosis in 68% and 
normalization of intra-ocular pressure in 42% of diabetic patients treated with PRP (Ohnishi, 
1994). The importance of applying an adequate dose of PRP has been demonstrated 
(Simmons, 1980). As well as laser treatment, the Diabetes Control and Complications trial 
(DCCT) showed that lowering blood glucose reduces risk of visual loss due to retinopathy 
by 76% (The Diabetes Control and Complications Trial Research Group, 1993). 
A multicentre prospective clinical trial by the Central Vein Occlusion Study (CVOS) group 
investigated the role of pan-retinal photocoagulation (PRP) in ischaemic CRVO (The Central 
Vein Occlusion Study Group, 1995). The gold-standard management of ischaemic CRVO, as 
derived from this study, is that of prompt PRP of eyes which develop two clock hours of 
iris/angle neovascularization. This is still a matter of controversy, as pointed out by Hayreh 
SS et al recently, stating that “approximately one-third of the eyes with iris NV and treated 
with PRP would never have developed NVG” (Hayreh, 1983). It is recommended that PRP 
is performed at the first sign of rubeosis (Hayreh, 1990b; Magargal, 1982).  
Management of ocular ischaemic syndrome is difficult. PRP cannot be used in OIS. This is 
supported by the fact that retinal capillary non-perfusion has not been shown to occur on 
fundus fluorescein angiography in OIS (Mizener, 1997). In patients with neurological 
symptoms, there is an indication for carotid endarterectomy, which may lead to regression of 
new vessels. However, it can also paradoxically cause an intraocular pressure rise by restoring 
normal aqueous production. Nocturnal systemic hypotension should be avoided as it can 
precipitate ischaemic visual loss (Mizener, 1997), thus nightime anti-hypertensives should be 
avoided, and, when possible, beta-blocker drops are ideally not used for IOP control.  
Laser photocoagulation of areas of retinal nonperfusion has been advocated also in the 
treatment and/or prophylaxis of radiation retinopathy (Hykin, 1998). Single treatment with 
laser may, however, not be enough, and further laser might be needed at a later stage. Close 
follow-up is therefore recommended. As plaque brachytherapy creates a predictable zone of 
ischaemia, treating this zone with laser photocoagulation may prevent progression of 
radiation retinopathy (Finger, 2005). It has been hypothesized that this prevents ischaemic 
tissue from producing VEGF and cytokines responsible for causing new vessel proliferation, 
but further studies are required with respect to prophylactic treatment (Wen, 2009).  
Treatment of any ocular inflammatory disease consists of topical steroids and mydriatics, 
but may require systemic corticosteroids and/or immunosuppression, together with 
management of any underlying systemic disease.  
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5.2 Treatment of high IOP in NVG 
Unfortunately, the current literature on neovascular glaucoma has only few articles that 
provide strong evidence in support of certain therapeutic recommendations (Sivak-Callcott, 
2001).  
5.2.1 Medical therapy 
Medical therapy is the first step in managing NVG by suppressing aqueous production, 
hence decreasing intraocular pressure. Beta-blockers, topical and oral carbonic anhydrase 
inhibitors and alpha-2-adrenergic agonists are used, whereas prostaglandin analogues, 
which work by increasing uveal outflow, are not useful if the angle is closed. Topical 
corticosteroids are used concurrently to treat any associated inflammation. Atropine may be 
used for its cycloplegic effect in addition to increasing uveoscleral outflow. Pilocarpine and 
anticholinergic agents are contra-indicated as they increase inflammation, cause miosis, 
worsen synechial angle closure and decrease uveoscleral outflow. In most cases of NVG, 
medical therapy is not enough to control IOP and prevent visual loss.  
5.2.2 Glaucoma filtering surgery 
Glaucoma filtering surgery for NVG, in the form of trabeculectomy, is often unsuccessful 
(Mietz, 1999). This has therefore been augmented with antimetabolites, mitomycin C (MMC) 
or 5-fluorouracil (5-FU). They help modulate the wound healing process to lessen scar 
formation around the scleral flap in trabeculectomy, which is the commonest cause of 
surgical failure. Both MMC and 5-FU have been shown to improve the success rate of 
trabeculectomy in eyes with NVG (Tsai, 1995; Hyung, 2001). Previous studies suggest that 
the use of MMC is superior to 5-FU in the surgical management of refractory glaucoma 
(Katz, 1995; Sisto, 2007; Skuta, 1992). However, the prognosis of augmented trabeculectomy 
remains poor in NVG (Sisto, 2007), and a success rate of 28% at 5 years has been reported 
after filtering surgery with 5-FU for NVG (Tsai, 1995). Poor prognostic factors for MMC-
augmented trabeculectomy in NVG include young age (less than 50 years), previous 
vitrectomy (which may be due to conjunctival scarring, intra-ocular inflammation and 
increased diffusion of vasoproliferative factors) (Takihara, 2009; Kiuchi, 2006), presence of 
pseudophakia (Al Obeidan, 2008) and presence of proliferative retinal membranes or retinal 
detachment (Kiuchi, 2006). Adequate pan-retinal photocoagulation performed prior to 
trabeculectomy has been shown to improve the effectiveness of surgery (Al Obeidan, 2008).  
There have also been reports of MMC-trabeculectomy combined with amniotic membrane 
grafts under the scleral flap for improved intra-ocular pressure control and increased 
surgical success (Sheha, 2008; Fujishima, 1998; Bruno, 2006), due to its anti-inflammatory, 
anti-fibrotic and anti-angiogenic properties.  
 
5.2.3 Anti-VEGF therapy 
Anti-VEGF therapy (bevacizumab) has been successfully used as adjunctive therapy in 
addition to augmented trabeculectomy (Kotecha, 2011; Spiteri Cornish 2009; Alkawas, 2010; 
Fakhraie, 2010; Saito, 2010). As discussed above, VEGF has a key role in the pathogenesis of 
NVG. The role of anti-VEGF therapy in neovascular glaucoma has been described as being 
twofold – control of the neovascular process, and modulation of the healing process at the 
trabeculectomy site (Spiteri Cornish, 2009). However, anti-VEGF cannot be used alone to 
treat NVG, but is used only as an adjunct to PRP, medical therapy and surgery.  
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Endothelial cells in rubeotic vessels are different from normal iris vessels (Williams, 1988; 
Miller, 1984) and one of the effects of VEGF on new vessel formation is mediated through 
formation of fenestrations, thus causing vascular hyperpermeability. A single dose of 
intravitreal bevacizumab (Avastin®, Genentech, South San Francisco, CA, USA) has been 
shown to induce vascular endothelial cell apoptosis in immature vessels and induce 
maturation of premature vessels characterized by disappearance of fenestrations and an 
increase in pericyte coverage (Kohno, 2010). Further studies confirm that intravitreal 
injection of bevacizumab reduces vascular permeability (Ishibashi, 2010). The characteristic 
hyperpermeability of vessels formed in pathologic angiogenesis may be responsible for the 
ocular pain in NVG. This is likely the result of increased presence of inflammatory 
mediators in the eye. A recent study suggests that intra-vitreal bevacizumab can be used to 
control pain in refractory NVG, despite a modest intra-ocular pressure reduction (Kotecha, 
2011). This confirms previous observations of anti-VEGF resulting in rapid relief of 
symptoms in NVG (Iliev, 2006).  
Studies show that anti-VEGF also reduced scar formation during wound healing, showing 
that VEGF strongly influenced scar tissue formation (Wilgus, 2008; Li, 2009; Nissen, 1998). 
The most important cause of failure of trabeculectomy is persistent inflammation followed 
by fibrosis at the site of the scleral flap, preventing the formation of an adequate draining 
bleb (Vote, 2004).  
Several case series report rapid regression of anterior segment neovascularization following 
an intra-vitreal injection of bevacizumab in NVG (Iliev, 2006; Moraczewski, 2009; 
Wakabayashi, 2008; Mason 2006b; Silva, 2006), and has been used in NVG secondary to 
diabetic retinopathy (Avery, 2006; Mason, 2006; Oshima, 2006), CRVO (Iliev, 2006) and 
ocular tumours (Yeung, 2010). However, duration of action of bevacizumab is about four 
weeks and multiple injections may be necessary (Fakhraie, 2010).  
Based on the case series and small studies in literature, pre-operative intravitreal 
bevacizumab combined with MMC-augmented trabeculectomy seems to be an effective 
method of controlling intra-ocular pressure and pain in NVG. It has also been observed that 
prognosis is better if there is less delay between diagnosis and treatment (Fakhraie, 2010). 
The long-term efficacy of this therapy is however unknown and repeat injections may be 
required, much like in age-related macular degeneration. Randomized-controlled trials are 
needed to further assess the efficacy and safety of this treatment option for NVG.  
 
5.2.4 Valve implant surgery 
Aqueous tube shunts are used in NVG when there is a high risk of failure from conventional 
filtering surgery. Various devices have been described, including Molteno implant, 
Baerveldt implant, Ahmed valve, Schocket tube and Krupin valve.  
The Ahmed valve was designed to prevent post-operative hypotony, and is theoretically 
open only at intraocular pressures of more than 8mmHg. Complications associated with it 
include hypotony, anterior chamber shallowing, choroidal detachments, hyphaema, tube 
malposition or occlusion, and restrictive ocular motility. Hyphaema is the most prevalent 
complication, occurring in 14% of cases in one study (Kim, 2003). The tube can be placed in 
the anterior chamber, sulcus or vitreous cavity (Rush, 2009; Netland, 2009). The Ahmed 
Glaucoma Valve was shown to be successful in lowering IOP in the short and intermediate 
term in NVG, but in the long term, the implant failed to control IOP (Yalvac, 2007), and 
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success rate with AVG in NVG is statistically significantly lower than other types of 
glaucoma (Netland, 2009).  
Similarly, the Molteno implant was shown to reduce IOP up to 5 years in a prospective 
study (Every, 2006; Broadway, 2001), the success rate progressively decreasing thereafter 
(Yalvac 2007; Every, 2006). In the largest study of Molteno implants in NVG, successful IOP 
control occurred in 62% of eyes at 1 year and 10.3% at 5 years (Mermoud, 1993). Prognosis 
remained poor, and loss of vision occurred in 48% and phthisis in 18%, the worst off being 
NVG secondary to CRVO.  
Baerveldt implants are seen as an effective and safe treatment for intermediate-term IOP 
control in patients with NVG (Sidoti, 1995; Krishna, 2001). Twelve-month IOP success rates 
was 79% (compared to 56% at 18 months) in one report (Sidoti, 1995). However, many 
patients lose visual acuity despite IOP control because of the severity of their underlying 
retinal disease. Baerveldt implants have also been combined with pars-plana vitrectomy, 
allowing management of vitreo-retinal pathology at the same time, such as 
endophotocoagulation, removal of any media opacities and repair of retinal detachment. 
Results were encouraging in documented case series of pars plana Baerveldt implant (PPBI), 
with success rates for IOP control of 91% (Luttrull, 1995) and 94% (Chalam, 2002), and 
preservation of visual acuity in 91%. Complications of anterior chamber placed tubes are 
avoided, including endothelial touch, shallow anterior chambers, uveitis, cataract, tube 
obstruction and hyphaema. This was also seen with Ahmed valves (Faghihi, 2007) and 
Molteno implants (Lloyd, 1991) where the tube was implanted in the vitreous cavity and the 
procedure combined with a pars-plana vitrectomy, with good results. However, posterior 
segment complications such as retinal detachment, obstruction of the tube with vitreous, 
epiretinal membrane and cystoid macular oedema means that the procedure should be used 
in selected cases only, namely glaucomatous eyes with shallow anterior chambers and with 
associated vitreoretinal pathology such as vitreous haemorrhage (Faghihi, 2007; Hong, 
2005).  
A systematic review of literature on glaucoma drainage devices concluded that Molteno 
implant, Baerveldt implant, Ahmed valve and Krupin valve showed no statistically 
significant difference in IOP change or overall success rate (Hong, 2005).  
5.2.5 Cycloablative treatment 
Cyclodestructive procedures are used as a last resort in NVG, to reduce intra-ocular 
pressure. Various methods have been used with the sole purpose of partially destroying the 
ciliary body, hence reducing aqueous production. Cyclodiathermy was replaced by 
cyclocryotherapy, which was then superseded by laser ablative treatment using Nd:YAG or 
diode laser using a transscleral approach. Cyclocryotherapy is associated with more pain 
and is therefore less tolerated than laser therapy (Hayreh, 2007), and may be associated with 
a higher complication rate (Goldenberg-Cohen, 2005; Silvak-Callcott, 2001). Sympathetic 
ophthalmia, retinal detachment, anterior segment ischaemia and phthisis bulbi have been 
reported with cyclocyrotherapy.  
Diode laser cyclophotocoagulation (DCPC) is very effective in reducing intra-ocular 
pressure in refractory glaucoma, with single or repeated treatments (Iliev, 2007), with the 
overall success rate quoted as 70%, with a 35-55% reduction in IOP (Bloom, 1997; 
Noureddin, 2006; Murphy, 2003; Ansari, 2007). This is comparable to intraocular pressure 
reduction produced by Ahmed Glaucoma Valve (AGV) implantation in NVG (Yildirim, 
2009). It is more effective than continuous wave YAG laser, and equivalent to free running 
www.intechopen.com
 
Glaucoma – Current Clinical and Research Aspects 
 
136 
Nd:YAG laser (Oguri, 1998). DCPC combined with PRP could be more effective than DCPC 
alone (Rehak, 1994). Micropulse DCPCis comparable to conventional cyclodiode laser. 
However, there are complications associated with cyclophotocoagulation therapy, hypotony 
occurring in 15-20% of cases (Murphy, 2003; Iliev 2007). Other complications include loss of 
vision, corneal decompensation, necrotizing scleritis, hyphaema and phthisis bulbi (Yap-
Veloso, 1998; Shen, 2004; Leszczyńsk, 2008; Hampton, 1990).  
Ciliary body excision has been documented, but is associated with very high complication 
rates including vitreous haemorrhages, vitreous loss, expulsive haemorrhages, hypotony, 
retinal detachment and phthisis bulbi (Sautter, 1984).  
Although cyclodiode ablation seems to be effective in reducing IOP in refractory NVG, its 
long term success rate has not been well described yet.  
5.2.6 Photodynamic Therapy (PDT) 
Photodynamic therapy with verteporfin recently has proven to be effective in partially 
obliterating anterior segment neovascularization in NVG secondary to ischaemic CRVO 
(Parodi, 2004; Parodi, 2005; Parodi, 2007). This had been previously proposed in animal 
experimental models (Packer, 1984; Miller, 1991; Husain, 1997). It was reported that PDT 
causes an overall IOP decrease of 39% (Parodi, 2005) and significant involution of iris and 
angle neovascularization (Parodi, 2007). It is postulated that up-regulation and release of 
proangiogenic factors in ischaemic CRVO has a temporary effect, and when angle and iris 
neovascularization are limited (in this case by PDT), this pro-angiogenic stimulus may 
gradually dissipate, and subsequent growth of new vessels is limited. Although 
encouraging, further studies are required to assess the role and efficacy of PDT in NVG.  
5.2.7 Management of the painful blind eye 
Neovascular glaucoma is a very difficult condition to manage, and visual outcome does not 
always follow IOP control due to the underlying ocular disease. Blindness can ensue, which 
may be very painful due to high intraocular pressure and inflammation. Keeping the eye 
comfortable requires topical corticosteroids, cycloplegics, cycloablation and even alcohol 
injection. The last resort is enucleation (or in some cases, evisceration). It is the duty of the 
ophthalmologist to remind the patient that the latter requires maintenance and compliance.  
5.3 Summary of treatment 
Clinical recommendations for diagnosis and treatment of NVG, based on an evidence-based 
systematic review, are listed in table 3 (Sivak-Callcott, 2001; Hayreh, 2007).  
 
Diagnosis of NVG 
 High level of suspicion about neovascularization (NV) in conditions at high risk 
 (diabetic retinopathy, ischaemic CRVO, ocular ischaemic syndrome, amongst 
 others) 
 Full ocular examination, especially undilated gonioscopy 
 Fundus fluorescein angiography may help identify areas of retinal ischaemia 
 Anterior segment fluorescein angiography may help identify neovascularization 
 Electroretinography may help estimate the risk of anterior segment NV.  
Treatment of NVG 
 Treatment of underlying disease (see text) 
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 Prompt medical treatment of elevated IOP and any ocular inflammation 
 Glaucoma surgery to preserve vision if medical treatment insufficient (filtering 
 surgery; valve implant surgery, with/without anti-VEGF) 
Painful blind eyes are managed with topical corticosteroids, cycloplegics, cycloablation, 
 and as a last resort, enucleation/evisceration 
Table 3. Clinical recommendations for diagnosis and treatment of NVG 
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